High concentrations of uric acid inhibit angiogenesis via regulation of the krüppel-like factor 2-vascular endothelial growth factor-a axis by miR-92a

Circulation Journal

Volumn 79, Issue 11, 2015, Pages 2487-2498

  Yu, Shandong ^a,b   Hong, Quan ^a   Wang, Yuanda ^a   Hou, Kai ^a   Wang, Liyuan ^a   Zhang, Yang ^a   Fu, Bo ^a   Zhou, Yunan ^a   Zheng, Wei ^a   Chen, Xiangmei ^a   Wu, Di ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Angiogenesis; KLF2; MiR 92a; Uric acid; VEGFA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; KRUPPEL LIKE FACTOR 2; MICRORNA; MICRORNA 92A; UNCLASSIFIED DRUG; URIC ACID; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; KLF2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MIRN92 MICRORNA, HUMAN; VEGFA PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERURICEMIA; IMMUNOBLOTTING; LUCIFERASE ASSAY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MRNA EXPRESSION ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUBE FORMATION ASSAY; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; BINDING SITE; BIOLOGY; CASE CONTROL STUDY; CELL CULTURE; DNA MICROARRAY; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; PROMOTER REGION; SIGNAL TRANSDUCTION;

ADULT; ANGIOGENESIS INHIBITORS; BINDING SITES; CASE-CONTROL STUDIES; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERURICEMIA; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSFECTION; URIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84944754579     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0283     Document Type: Article

References (34)

1. Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J 2012; 42: 997-1007
2. Crittenden DB, Pillinger MH. The year in gout: 2011–2012. Bull NYU Hosp Jt Dis 2012; 70: 145-151
3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63: 3136-3141
4. Johnson RJ, Kang DH, Feig D, Kivilghn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease. Hypertension 2003; 41: 1183-1190
5. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, et al. Serum uric acid: A risk factor and a target for treatment. J Am Soc Nephrol 2006; 17(4 Suppl 2): S69-S73
6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1121
7. Numa S, Hirai T, Nakagawa K, Ohara K, Fukuda N, Nozawa T, et al. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically lowintermediate risk. Circ J 2014; 78: 1600-1605
8. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
9. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-1713
10. Dang LT, Lawson ND, Fish JE. MicroRNA control of vascular endothelial growth factor signaling output during vascular development. Arterioscler Thromb Vasc Biol 2013; 33: 193-200
11. Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu QF, et al. Inhibition of MicroRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013; 128: 1066-1075
12. Yamada N, Nakagawa Y, Tsujimura N. Role of intracellular and extracellular MicroRNA-92a in colorectal cancer. Transl Oncol 2013; 6: 482-492
13. Gene Ontology Consortium. The Gene Ontology (GO) project in 2006. Nucleic Acids Res 2006; 34: D322-D326
14. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29
15. Dupuy D, Bertin N, Hidalgo CA, Venkatesan K, Tu D, Lee D, et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat Biotechnol 2007; 25: 663-668
16. Schlitt T, Palin K, Rung J, Dietmann S, Lappe M, Ukkonen E, et al. From gene networks to gene function. Genome Res 2003; 13: 2568-2576
17. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, et al. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem 2005; 280: 28848-28851
18. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309
19. dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D’Amore PA. Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci 2012; 125: 831-843
20. Wiik BP, Larstorp AC, Høieggen A, Kjeldsen SE, Olsen MH, Ibsen H, et al. Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE study. Am J Hypertens 2010, 23: 845-851
21. Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 dia betes: Results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-1343
22. Causevic A, Semiz S, Macic Dzankovic A, Cico B, Dujic T, Malenica M, et al. Relevance of uric Acid in progression of type 2 diabetes mellitus. Bosn J Basic Med Sci 2010; 10: 54-59
23. Puig JG, Torres RJ, Ruilope LM, Campo C, Grande C, Sancho T, et al. The pathophysiology of hyperuricemia in essential hypertension: A pilot study. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1197-1199
24. Quan H, Peng X, Liu S, Bo F, Yang L, Huang Z, et al. Differentially expressed protein profile of renal tubule cell stimulated by elevated uric acid using SILAC coupled to LC-MS. Cell Physiol Biochem 2011; 27: 91-98
25. Hong Q, Qi K, Feng Z, Huang Z, Cui S, Wang L, et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium 2012; 51: 402-410
26. Kang DH PS, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
27. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012; 32: 979-987
28. Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest 2006; 116: 49-58
29. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006; 107: 4354-4363
30. Zhang X, Hong Q, Hou K, Wang Y, Wu D, Chen X. High concentration uric acid regulates endothelial function via miR-155. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33: 1141-1145 (in Chinese).
31. De Rosa S, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J 2014; 78: 567-575
32. Izawa H, Amano T. Plasma microRNA-100 as a biomarker of coronary plaque vulnerability: A new generation of biomarker for developing acute coronary syndrome. Circ J 2015; 79: 303-304
33. De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J 2014; 78: 1775-1781
34. Caroli A, Cardillo MT, Galea R, Biasucci LM. Potential therapeutic role of microRNAs in ischemic heart disease. J Cardiol 2013; 61: 315-320.